ICCC
ImmuCell Corporation
9.80$
-1.4%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.6% | +42.4% | -24.6% | +9.8% | +28.9% | +4.1% | -20.1% | -14.6% | +38.5% | +35.8% | -30.6% | – | |
| – | -7.1% | +29.3% | -14.5% | +4.4% | +11.1% | -4.2% | -23.0% | -13.3% | +50.0% | +20.9% | -16.7% | – | |
| – | -0.7% | +82.5% | -46.4% | +28.7% | +78.8% | +18.4% | -16.0% | -16.1% | +23.2% | +60.0% | -47.7% | – | |
| – | -4.7% | +18.4% | -18.4% | -23.7% | +4.2% | -7.6% | +9.9% | -16.5% | +9.3% | -58.1% | -62.3% | – | |
| – | +132.0% | -55.5% | +13.1% | -12.2% | +5.0% | +166.7% | -51.3% | +1.2% | +54.6% | +0.9% | +11.8% | – | |
| – | -7.7% | +14.8% | +0.8% | -17.5% | +2.4% | +214.4% | -67.6% | +4.2% | +26.7% | -9.4% | -81.3% | – | |
| – | – | – | – | – | – | +79.9% | -49.0% | -96.5% | -388.7% | – | -1.7% | – | |
| – | +14.1% | -11.5% | -2.5% | -6.4% | -6.0% | -6.6% | +6.6% | +7.8% | -23.4% | -3.2% | -4.0% | – | |
| – | – | – | – | – | – | +178.3% | -65.2% | -126.9% | – | – | -3.8% | – | |
| – | +773.4% | -33.0% | +0.0% | +0.0% | +350.4% | -68.5% | +0.0% | +134.0% | -25.8% | +278.8% | +267.0% | – | |
| – | – | – | – | – | – | +181.2% | -65.3% | -127.8% | – | – | -5.5% | – | |
| – | – | – | -290.3% | – | +1,216.8% | +35.9% | -27.7% | -58.1% | -474.5% | – | -5.2% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.